Mesenchymal–epithelial transition factor (MET)-activating alterations, including overexpression (15–70%), amplification (2–5%), and exon 14 (METex14) skipping mutations (3–4%), are oncogenic drivers in 5–9% of newly diagnosed non-squamous NSCLC [5,6]. Here, MET is linked to non-small cell lung carcinoma.